12:00 AM
 | 
Mar 29, 1999
 |  BC Week In Review  |  Company News  |  Deals

Ribozyme, Eli Lilly deal

The companies will develop ribozyme therapeutics to treat hepatitis C virus (HCV) infection. RZYM could receive up to $38 million, including $9.2...

Read the full 88 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >